Sign in Subscribe
Universities and colleges

Promoter Methylation Pattern Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma

Strategic Insights

— 1 min read

Recent research published in Clinical Cancer Research has identified a correlation between promoter methylation patterns in the N-methyl-D-aspartate receptor 2B (NMDAR2B) gene and poor prognosis in patients with esophageal squamous cell carcinoma (ESCC). The study, conducted by scientists in the United States, analyzed the methylation status of the NMDAR2B gene in 67 ESCC tissues, including 43 primary tumors with well-characterized clinicopathologic variables. The researchers found that patients with higher NMDAR2B methylation ratio in the proximal region (P1) had a worse 5-year disease-specific survival rate than those without NMDAR2B methylation.

Key Takeaways:

  • The study investigated the correlation between promoter methylation patterns in the NMDAR2B gene and clinical features of human ESCC.
  • The researchers analyzed the methylation status of the NMDAR2B gene in 67 ESCC tissues, including 43 primary tumors with well-characterized clinicopathologic variables.
  • Using an optimized cutoff value, the study found that patients with higher NMDAR2B methylation ratio in the proximal region (P1) showed a worse 5-year disease-specific survival rate than those without NMDAR2B methylation.
  • The researchers concluded that NMDAR2B promoter methylation could be a clinically applicable marker in ESCC.
  • The study was conducted by scientists in the United States, specifically in the Head and Neck Cancer Research Division at Johns Hopkins University.
  • The study was published in Clinical Cancer Research, a journal published by the American Association for Cancer Research.

Statistics:

  • 67 ESCC tissues were analyzed in the study.
  • 43 primary tumors with well-characterized clinicopathologic variables were included.
  • 3 independent modalities for methylation analysis were used: bisulfite sequencing, combined bisulfite restriction analysis, and TaqMan methylation-specific PCR.
  • The study found that patients with higher NMDAR2B methylation ratio in the proximal region (P1) had a worse 5-year disease-specific survival rate than those without NMDAR2B methylation (p The optimized cutoff value was based on quantitative methylation-specific PCR.
  • The study was published in Clinical Cancer Research (Volume 13, Issue 22 Part 1, 2007).

Sources:

  • A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma. Clinical Cancer Research, 2007;13(22 Pt 1):6658-65.
  • American Association for Cancer Research. Clinical Cancer Research. 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.
  • Health & Medicine Week editors. Copyright 2007, Health & Medicine Week via NewsRx.com.

Read more